0.00
+0(+0.00%)
Currency In USD
Address
186 Alewife Brook Parkway
Cambridge, MA 02138
United States of America
Phone
617-780-1598
Website
Sector
Healthcare
Industry
Biotechnology
Employees
N/A
First IPO Date
October 07, 2022
| Name | Title | Pay | Year Born |
| Dr. Daniel R. Vlock M.D. | Co-Founder, Pres, Chief Executive Officer & Director | 0 | 1952 |
| Mr. Thomas T. Thomas II, C.F.A., CFA | Chief Financial Officer | 0 | 1958 |
| Dr. Christine de los Reyes M.B.A., Pharm.D., PharmD | Chief Bus. Officer & Chief Commercialization Officer | 0 | 1954 |
| Dr. Gerald B. Pier Ph.D. | Co-Founder, Chief Scientific Officer & Chair of Scientific Advisory Board | 0 | 1952 |
| Dr. William W. Chin M.D. | Senior Strategic Advisor & Director | 0 | 1948 |
Alopexx, Inc., a clinical stage biotechnology company, focusing on developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections. Its lead products include Vaccine AV0328, a synthetic poly N-acetyl glucosamine (PNAG) vaccine that has completed Phase I first-in-man trial for the treatment of streptococcus pneumoniae, meningococcal infections, Alzheimer's disease, and type 1 diabetes mellitus; and F598, a monoclonal antibody that has completed Phase I and pilot Phase II trials for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units. The company is headquartered in Cambridge, Massachusetts.